Samer Al Hadidi

Samer Al Hadidi

Hematologist, Medical Oncologist

Myeloma

University of Arkansas for Medical Sciences

Location USA, Little Rock

Linkedin

X

Dr. Samer Al Hadidi is a Hematologist and Medical Oncologist specializing in multiple myeloma and hematologic malignancies. He is actively involved in clinical research, medical education, and academic leadership, with a strong focus on clinical trials, health disparities, and advanced therapeutic approaches in oncology.

Current Position

  • Associate Professor, College of Medicine, Division of Hematology and Oncology, Myeloma Section, University of Arkansas for Medical Sciences
  • Board Member, Specialty Board and Advisory Committee, Hematology Board, American Board of Internal Medicine

Education

  • Fellowship in Hematology/Medical Oncology, Baylor College of Medicine, Houston, Texas
  • Master’s in Clinical Research and Statistical Analysis (MS CRDSA), University of Michigan, Ann Arbor, Michigan – conferred with highest honors
  • Residency in Internal Medicine, Michigan State University, Flint, Michigan
  • Medical Doctor, University of Jordan, Amman – conferred with highest honors

Professional Experience

  • Assistant Professor, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (2021–2024)
  • Core Faculty, Hematology and Medical Oncology Fellowship Program, University of Arkansas for Medical Sciences (since 2021)
  • Assistant Professor, Department of Medicine, Michigan State University, Flint, Michigan
  • Core Faculty, Internal Medicine Residency Program, Michigan State University
  • Core Faculty, Transitional Year Residency Program, Michigan State University

Research / Publications / Academic Activity

  • Author of an extensive number of peer-reviewed publications indexed in major journals such as JAMA Oncology, Blood, Journal of Clinical Oncology, and others
  • Principal Investigator and Sub-investigator in multiple clinical trials focused on multiple myeloma and hematologic malignancies
  • Active research involvement in health disparities, CAR-T cell therapy, bispecific antibodies, and outcomes in multiple myeloma
  • Editorial Board Member for journals including Cancer Treatment and Research Communications, JAP Academy Journal, and Cell Therapy Next
  • Reviewer for multiple high-impact journals including Journal of Clinical Oncology, JAMA Oncology, Blood, and Cancer

Area of Specialization

  • Hematology
  • Medical Oncology
  • Multiple Myeloma
  • Hematologic Malignancies

Additional Information

  • Board Certified in Internal Medicine (2016), Hematology (2021), and Medical Oncology (2021)
  • Active member of professional societies including ASCO, ASH, AACR, International Myeloma Society, and others
  • Recipient of multiple awards including Conquer Cancer Merit Award (2020) and Healio Disruptive Innovators Award (2023)
  • Principal Investigator on multiple funded research grants in multiple myeloma